Paradiem, LLC Catalyst Pharmaceuticals, Inc. Transaction History

Paradiem, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Apr 22, 2024	SELL	$13.18 - $17.11 $223,058 - $289,569	-16,924 Reduced 8.54%	181,295 $2.89 Million
Q4 2023 Feb 05, 2024	BUY	$11.78 - $17.29 $368,878 - $541,419	31,314 Added 18.76%	198,219 $3.33 Million
Q3 2023 Oct 30, 2023	SELL	$11.69 - $15.02 $882,782 - $1.13 Million	-75,516 Reduced 31.15%	166,905 $1.95 Million
Q2 2023 Jul 18, 2023	BUY	$11.5 - $18.08 $66,619 - $104,737	5,793 Added 2.45%	242,421 $3.26 Million
Q1 2023 Apr 10, 2023	BUY	$14.34 - $21.05 $3.39 Million - $4.98 Million	236,628 New	236,628 $3.92 Million

327

94.1M

19.1K

51.1K

Ticker CPRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 102,820,000
Market Cap $2.33B
Description
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...

Get notified when there are updates to the investment portfolio of Paradiem, LLC, based on Form 13F filings with the SEC.

Stay updated on Paradiem, LLC with notifications on news.